Huang Yvonne J, Boushey Homer A
1 Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan; and.
2 Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, California.
Ann Am Thorac Soc. 2015 Nov;12 Suppl 2(Suppl 2):S176-80. doi: 10.1513/AnnalsATS.201506-319AW.
Acute exacerbations of chronic obstructive pulmonary disease (COPD) are thought to be associated with--and perhaps to mediate--accelerated loss of lung function in COPD. Although the application of culture-independent methods for detection of bacteria have shown COPD to be associated with marked differences in the burden, diversity, and composition of the bronchial bacterial microbiome, few studies have examined the changes associated with community-acquired exacerbations of the disease. In a longitudinal cohort study of COPD, the availability of sputum samples from subjects obtained at the onset of an exacerbation and during periods of clinical stability before and after the event enabled us to recently address this gap in knowledge, using culture-independent, 16S rRNA-based analysis methods combined with in silico inference of metagenomic functions. We observed sputum bacterial composition to be generally stable over the preexacerbation period of clinical stability, but to change at the time of exacerbation, with specific enrichment in not only typical COPD-associated bacterial species (e.g., Haemophilus influenzae) but also other phylogenetically related species with pathogenic potential. Concurrently, we observed depleted abundance of other bacteria whose predicted metagenomes suggest functional capacities to produce a variety of antiinflammatory compounds. Most strikingly, we found that resolution of these exacerbation-related changes in sputum microbiota composition differed significantly, depending on the exacerbation treatments prescribed. Treatment with corticosteroids resulted in microbiome enrichment for a number of bacterial communities, mostly members of the Proteobacteria phylum, whereas prolonged suppression of microbiota was seen in those treated with antibiotics alone. Taken together, our findings suggest that exacerbations of COPD are associated with heterogeneous changes in the bronchial microbiome, with increases in the abundance of species related to typical COPD pathogens and decreases in microbiota members that contribute to compositional and functional homeostasis. The findings further suggest that exacerbation treatments may have very different impacts on the bronchial microbiome's rate of return toward baseline composition.
慢性阻塞性肺疾病(COPD)的急性加重被认为与COPD患者肺功能的加速丧失有关,甚至可能在其中起到介导作用。尽管采用非培养方法检测细菌已显示COPD与支气管细菌微生物群的负荷、多样性及组成存在显著差异,但很少有研究探讨与该疾病社区获得性加重相关的变化。在一项针对COPD的纵向队列研究中,由于能够获取受试者在急性加重发作时以及发作前后临床稳定期的痰液样本,我们最近利用基于16S rRNA的非培养分析方法并结合宏基因组功能的计算机推断,填补了这一知识空白。我们观察到,在临床稳定的加重前阶段,痰液细菌组成总体稳定,但在急性加重时会发生变化,不仅典型的COPD相关细菌种类(如流感嗜血杆菌)会特异性富集,其他具有致病潜力的系统发育相关菌种也会富集。同时,我们观察到其他一些细菌的丰度降低,其预测的宏基因组显示这些细菌具有产生多种抗炎化合物的功能能力。最引人注目的是,我们发现痰液微生物群组成中这些与急性加重相关的变化的消退情况因所规定的急性加重治疗方法而异。使用皮质类固醇治疗导致多个细菌群落的微生物群富集,其中大多数是变形菌门的成员,而单独使用抗生素治疗的患者则出现微生物群的长期抑制。综上所述,我们的研究结果表明,COPD急性加重与支气管微生物群的异质性变化有关,与典型COPD病原体相关的菌种丰度增加,而有助于维持组成和功能稳态的微生物群成员减少。这些研究结果还表明,急性加重治疗可能对支气管微生物群恢复至基线组成的速度产生非常不同的影响。